{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:50:31Z","timestamp":1791345031204,"version":"4.3.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2010,6,15]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Antiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetic patients. However, the efficacy and usefulness of 2 different antiplatelet drugs, aspirin and cilostazol, in the progression of carotid intima-media thickening are unknown.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted a prospective, randomized, open, blinded end point study in 4 East Asian countries. A total of 329 type 2 diabetic patients suspected of peripheral artery disease were allocated to either an aspirin-treated (81 to 100 mg\/d) group or a cilostazol-treated (100 to 200 mg\/d) group. The changes in intima-media thickness of the common carotid artery during a 2-year observation period were examined as the primary end point. The regression in maximum left, maximum right, mean left, and mean right common carotid artery intima-media thickness was significantly greater with cilostazol compared with aspirin (\u22120.088\u00b10.260 versus 0.059\u00b10.275 mm,\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001; \u22120.042\u00b10.274 versus 0.045\u00b10.216 mm,\n            <jats:italic>P<\/jats:italic>\n            =0.003; \u22120.043\u00b10.182 versus 0.028\u00b10.202 mm,\n            <jats:italic>P<\/jats:italic>\n            =0.004; and \u22120.024\u00b10.182 versus 0.048\u00b10.169 mm,\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001). In a regression analysis adjusted for possible confounding factors such as lipid levels and hemoglobin A\n            <jats:sub>1c<\/jats:sub>\n            , the improvements in common carotid artery intima-media thickness with cilostazol treatment over aspirin treatment remained significant.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            Compared with aspirin, cilostazol potently inhibited progression of carotid intima-media thickness, an established surrogate marker of cardiovascular events, in patients with type 2 diabetes mellitus.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Clinical Trial Registration\u2014<\/jats:italic>\n            <\/jats:bold>\n            URL: http:\/\/www.clinicaltrials.gov. Unique identifier: C000000215.\n          <\/jats:p>","DOI":"10.1161\/circulationaha.109.892414","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T01:41:40Z","timestamp":1275442900000},"page":"2584-2591","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":96,"title":["The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus"],"prefix":"10.1161","volume":"121","author":[{"given":"Naoto","family":"Katakami","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan (N.K., Y.Y.); Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea (Y.K.); and Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan (R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seol","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan (N.K., Y.Y.); Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea (Y.K.); and Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan (R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Kawamori","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan (N.K., Y.Y.); Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea (Y.K.); and Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan (R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan (N.K., Y.Y.); Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea (Y.K.); and Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan (R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)92635-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-S004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.12.3264"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.623"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000135654"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0740-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-5-16"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(99)00168-1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2001.tb00076.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.15.2683"},{"key":"e_1_3_2_13_2","first-page":"341","volume":"17","year":"1989","unstructured":"Takazakura E, Ohsawa K, Hamamatsu K. Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients. Jpn Pharmacol Ther. 1989; 17: 341\u2013345.","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.35191"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.18.12.1942"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00480-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400103"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.628875"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-4-199802150-00002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.545"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(00)00235-7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.1999.0010s2037.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000158263.64320.eb"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00147-6"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2004.05.002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.1.159"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2008.6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.108.164368"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802187200"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805711200"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.109.892414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:10:08Z","timestamp":1715580608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.109.892414"}},"subtitle":["Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2010,6,15]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,6,15]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.109.892414"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.109.892414","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,15]]},"assertion":[{"value":"2010-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}